PL322409A1 - Reversible protease inhibitors - Google Patents

Reversible protease inhibitors

Info

Publication number
PL322409A1
PL322409A1 PL96322409A PL32240996A PL322409A1 PL 322409 A1 PL322409 A1 PL 322409A1 PL 96322409 A PL96322409 A PL 96322409A PL 32240996 A PL32240996 A PL 32240996A PL 322409 A1 PL322409 A1 PL 322409A1
Authority
PL
Poland
Prior art keywords
protease inhibitors
reversible protease
reversible
inhibitors
protease
Prior art date
Application number
PL96322409A
Other languages
English (en)
Inventor
James T Palmer
David Rasnick
Jeffrey L Klaus
Original Assignee
Arris Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arris Pharm Corp filed Critical Arris Pharm Corp
Publication of PL322409A1 publication Critical patent/PL322409A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215Radicals derived from nitrogen analogues of carbonic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/26Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533Six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1016Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
PL96322409A 1995-03-24 1996-03-21 Reversible protease inhibitors PL322409A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40999695A 1995-03-24 1995-03-24
PCT/US1996/003844 WO1996030353A1 (en) 1995-03-24 1996-03-21 Reversible protease inhibitors

Publications (1)

Publication Number Publication Date
PL322409A1 true PL322409A1 (en) 1998-01-19

Family

ID=23622800

Family Applications (1)

Application Number Title Priority Date Filing Date
PL96322409A PL322409A1 (en) 1995-03-24 1996-03-21 Reversible protease inhibitors

Country Status (15)

Country Link
EP (1) EP0817778A1 (ko)
JP (1) JPH11503417A (ko)
KR (1) KR19980703261A (ko)
CN (1) CN1071751C (ko)
AU (1) AU713492B2 (ko)
CA (1) CA2216151A1 (ko)
CZ (1) CZ298197A3 (ko)
IL (1) IL117638A0 (ko)
MY (1) MY113489A (ko)
NO (1) NO311573B1 (ko)
NZ (1) NZ305626A (ko)
PL (1) PL322409A1 (ko)
TW (1) TW470750B (ko)
WO (1) WO1996030353A1 (ko)
ZA (1) ZA962336B (ko)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2251714A1 (en) 1996-04-22 1997-10-30 Massachusetts Institute Of Technology Suppression of immune response via inhibition of cathepsin s
EP0934293A1 (en) * 1996-07-30 1999-08-11 Arris Pharmaceutical Corporation Novel compounds and compositions for treating diseases associated with tryptase activity
DE19817461A1 (de) * 1998-04-20 1999-10-21 Basf Ag Neue substituierte Benzamide, deren Herstellung und Anwendung
JP2002538151A (ja) 1999-03-02 2002-11-12 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド カテプシンの可逆的インヒビターとして有用な化合物
DE60003702T2 (de) * 1999-09-13 2004-04-22 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Heterocyclische verbindungen als reversible inhibitoren von cysteinproteasen
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
CA2387805C (en) 1999-11-18 2012-08-28 Corvas International, Inc. Nucleic acids encoding endotheliases, endotheliases and uses thereof
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
ATE324372T1 (de) 2000-08-14 2006-05-15 Ortho Mcneil Pharm Inc Substituierte pyrazole
RU2317988C2 (ru) 2000-08-14 2008-02-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы, фармацевтическая композиция на их основе, применение фармацевтической композиции и способ ингибирования активности катепсина s
PT1309591E (pt) 2000-08-14 2007-04-30 Ortho Mcneil Pharm Inc Pirazoles substituídos
US7332494B2 (en) 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
US6579896B2 (en) 2000-09-06 2003-06-17 Ortho-Mcneil Pharmaceutical, Inc. Method for treating allergies using substituted pyrazoles
WO2002048097A1 (en) * 2000-12-12 2002-06-20 Corvas International, Inc. Compounds, compositions and methods for treatment of parasitic infections
JP2004523506A (ja) 2000-12-22 2004-08-05 アクシス・ファーマシューティカルズ・インコーポレイテッド カテプシン阻害剤としての新規な化合物と組成物
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
EP1436255A1 (en) * 2001-09-14 2004-07-14 Aventis Pharmaceuticals, Inc. Novel compounds and compositions as cathepsin inhibitors
WO2003024923A1 (en) * 2001-09-14 2003-03-27 Axys Pharmaceuticals, Inc. Sulfonamide compounds as protease inhibitors
KR20050044497A (ko) 2001-11-14 2005-05-12 아벤티스 파마슈티칼스 인크. 올리고펩티드 및 카텝신 s 억제제로서 이를 포함하는조성물
GB0311406D0 (en) * 2003-05-17 2003-06-25 Queen Mary & Westfield College Substituted phosphonate fluorescent sensors,and use thereof
SG191591A1 (en) 2008-05-21 2013-07-31 New World Lab Inc Selective caspase inhibitors and uses thereof
WO2010133000A1 (en) 2009-05-21 2010-11-25 New World Laboratories Inc. Selective caspase inhibitors and uses thereof
US8895497B2 (en) 2009-12-04 2014-11-25 Dcb-Usa, Llc Cathepsin S inhibitors
EP2697246B1 (en) 2011-04-15 2018-03-07 Genesis Technologies Limited Selective cysteine protease inhibitors and uses thereof
KR101309578B1 (ko) * 2011-05-06 2013-09-17 연세대학교 산학협력단 시스테인 프로테아제 선택성을 갖는 다이타이로신 화합물 및 이를 이용한 시스테인 프로테아제의 검출방법
KR101385855B1 (ko) * 2012-10-16 2014-04-22 이동익 카뎁신 검출용 다이아로마틱 아미노산 기질
US20200361967A1 (en) * 2018-01-19 2020-11-19 Osaka Soda Co., Ltd. Organosilicon compound and rubber composition comprising the same
EP3553521A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Gingivitis diagnostic methods, uses and kits

Also Published As

Publication number Publication date
MY113489A (en) 2002-03-30
TW470750B (en) 2002-01-01
WO1996030353A1 (en) 1996-10-03
NZ305626A (en) 2000-01-28
CN1184472A (zh) 1998-06-10
EP0817778A1 (en) 1998-01-14
NO311573B1 (no) 2001-12-10
AU713492B2 (en) 1999-12-02
JPH11503417A (ja) 1999-03-26
CN1071751C (zh) 2001-09-26
AU5367496A (en) 1996-10-16
NO974403D0 (no) 1997-09-23
CZ298197A3 (cs) 1998-03-18
ZA962336B (en) 1996-07-31
NO974403L (no) 1997-11-17
CA2216151A1 (en) 1996-10-03
IL117638A0 (en) 1996-07-23
KR19980703261A (ko) 1998-10-15

Similar Documents

Publication Publication Date Title
ZA962336B (en) Reversible protease inhibitors
PL326508A1 (en) Protease inhibitors
ZA964751B (en) Reversible cysteine protease inhibitors
IL131661A0 (en) Protease inhibitors
HU9601508D0 (en) Dp-iv-serine protease inhibitors
PL336589A1 (en) Serinic protease inhibitors
EP0744948A4 (en) PROTEASE INHIBITORS
HUP9903863A3 (en) Metalloproteinase inhibitors
PL328307A1 (en) Serinic protease inhibitors
PL336856A1 (en) Protease inhibitors
ZA983841B (en) Protease inhibitors
IL132629A0 (en) Protease inhibitors
PL328875A1 (en) Serinic protease inhibitors
ZA988479B (en) Protease inhibitors
PL328223A1 (en) Aspartil protease inhibitors
HUP9802764A3 (en) Guanidino protease inhibitors
ZA988064B (en) Protease inhibitors
ZA961225B (en) Serine protease inhibitors
EP0975612A4 (en) PROTEASE INHIBITORS
GB9500946D0 (en) Protease inhibitors
GB9520761D0 (en) Protease inhibitors
GB2318353B (en) Metalloproteinase inhibitors
GB9420277D0 (en) Protease inhibitors
GB9513320D0 (en) Metalloproteinase inhibitors
GB9503754D0 (en) Metalloproteinase inhibitors